{
    "Case ID": "008618",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent infringement dispute"
    ],
    "Legal_Issue": [
        "Whether Apotex's process for producing norfloxacin using protected piperazine infringes Merck's patented process under the 961 patent"
    ],
    "Governing_Law": [
        "Patented Medicines (Notice of Compliance) Regulations",
        "Patent Act"
    ],
    "Procedural_Stage": [
        "Application for prohibition"
    ],
    "Evidence_Assessment": [
        "Expert testimonies, patents, chemical processes"
    ],
    "Decision_Outcome": [
        "In favor of Merck"
    ],
    "Burden_of_Proof": [
        "On Merck to demonstrate infringement"
    ],
    "Credibility_Factor": [
        "Expert testimonies evaluated for credibility and technical accuracy"
    ],
    "Legal_Rule": [
        "A patented improvement does not grant rights to the original invention; obvious chemical equivalents infringe the original patent"
    ],
    "Standard_of_Review": [
        "Balance of probabilities"
    ],
    "Procedural_Issue": [
        "Regulatory approval pending patent expiry"
    ],
    "Grounds_for_Claim": [
        "Use of protected piperazine in a process that performs the same core reaction as the 961 patent"
    ],
    "Outcome_on_Merits": [
        "Apotex's process infringes Merck's patent"
    ],
    "Decision_Maker": [
        "Court"
    ],
    "Judicial_Review_Outcome": [
        "Prohibition granted"
    ],
    "Review_Standard": [
        "Substantial correctness of legal application and factual findings"
    ],
    "Procedural_Fairness_Assessment": [
        "Fair hearing with consideration of both parties' evidence and arguments"
    ],
    "Key_Evidence_Considered": [
        "Chemical process details, expert analysis, patent claims, process equivalence"
    ],
    "Legal_Framework": [
        "Patent law, regulatory framework for pharmaceutical approvals"
    ],
    "Applicant_Challenge": [
        "Merck challenged Apotex's regulatory submission based on patent infringement"
    ],
    "Court_Result": [
        "Merck succeeded; Apotex prohibited from obtaining regulatory approval until patent expiry"
    ],
    "Legal_Rule_Source": [
        "Patent Act, case law on equivalent infringement"
    ],
    "Standard_of_Proof": [
        "Preponderance of evidence"
    ],
    "Defendant_Response": [
        "Apotex argued its improved process with higher yield and purity did not infringe"
    ],
    "Evidence_Type": [
        "Documentary evidence, expert testimony, chemical data"
    ],
    "Remedy_Requested": [
        "Prohibition of regulatory approval for Apotex's product"
    ],
    "Outcome": [
        "Remedy granted; Apotex barred until patent expiration"
    ],
    "Decision_Authority": [
        "Federal Court or relevant patent court"
    ],
    "Remedy_Sought": [
        "Interim order preventing regulatory approval"
    ],
    "Resolution_Mechanism": [
        "Judicial determination"
    ],
    "Legal_Provision": [
        "Section 55.2(1) of the Patent Act, PM(NOC) Regulations"
    ],
    "Authority": [
        "Canadian Intellectual Property Office, Health Canada (regulatory context)"
    ],
    "Claimant_Status": [
        "Patent holder (Merck)"
    ],
    "Legal_Provision_Cited": [
        "Patent No. 961, Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Direct infringement via use of patented process through equivalent reagent"
    ],
    "Applicable_Process": [
        "Notice of Compliance (NOC) proceeding"
    ],
    "Outcome_of_Review": [
        "Application for prohibition granted"
    ],
    "Pending_Relief_or_Application": [
        "Regulatory approval delayed pending patent expiry"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Patented process infringement includes use of obvious chemical equivalents"
    ]
}